Aaron Philip Mitchell

Aaron Philip Mitchell

Auto-generated profile, based on publicly available information

Aaron Philip Mitchell

Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
AMAaron P. Mitchell
Aaron P. Mitchell
NTNiti U. Trivedi
Niti U. Trivedi
RGRenee L. Gennarelli
Renee L. Gennarelli
SCSusan Chimonas
Susan Chimonas
STSara M. Tabatabai
Sara M. Tabatabai
DKDeborah Korenstein
Deborah Korenstein
This systematic review of 36 studies examines associations between industry payments and physician prescribing. Background: Financial payments from the drug industry to U.S. physicians are common. Payments may influence physicians' clinical decision making and drug prescribing. Purpose: To evaluate whether r...

1 January 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EGErin F. Gillespie
Erin F. Gillespie
JYJoanna C. Yang
Joanna C. Yang
NMNoah J. Mathis
Noah J. Mathis
CMCatherine B. Marine
Catherine B. Marine
CWCharlie White
Charlie White
JYJonathan T. Yang
Jonathan T. Yang
In a multicenter RCT (n = 78), radiation to high-risk asymptomatic bone metastases ⬇ skeletal-related events and prolonged OS.

6 February 2019 in The Oncologist
Verified
Journal Article
Open access
PDF file
AMAaron P. Mitchell
Aaron P. Mitchell
AWAaron N. Winn
Aaron N. Winn
JLJennifer L. Lund
Jennifer L. Lund
SDStacie B. Dusetzina
Stacie B. Dusetzina
Background: Financial relationships between physicians and the pharmaceutical industry are common, but factors that may determine whether such relationships result in physician practice changes are unknown. Materials and Methods: We evaluated physician use of orally administered cancer drugs for four cancers: prostate (abiraterone, enzalutamide), renal cell (axitinib, everolimus, pazopanib, sorafenib, sunitinib), lung (afatinib, erlotinib), and chronic myeloid leukemia (CML; dasatinib, imatinib, nilotinib). Separate physician cohorts were defined for each cancer type by prescribing history. The primary exposure was the number of calendar years during 2013–2015 in which a physician received payments from the manufacturer of one of the studied drugs; the outcome was relative prescribing of that drug in 2015, compared with the other drugs for that cancer. We evaluated whether practice setting at a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, receipt of payments for purposes other than education or research (compensation payments), maximum annual dollar value received, and institutional conflict-of-interest policies were associated with the strength of the payment-prescribing association. We used modified Poisson regression to control confounding by other physician characteristics. Results: Physicians who received payments for a drug in all 3 years had increased prescribing of that drug (compared with 0 years), for renal cell (relative risk [RR] 1.81, 95% confidence interval [CI] 1.58–2.07), CML (RR 1.22, 95% CI 1.08–1.39), and lung (RR 1.69, 95% CI 1.58–1.82), but not prostate (RR 0.97, 95% CI 0.93–1.02). Physicians who received compensation payments or >$100 annually had increased prescribing compared with those who did not, but NCI setting and institutional conflict-of-interest policies were not consistently associated with the direction of prescribing change. Conclusion: The association between industry payments and cancer drug prescribing was greatest among physicians who received payments consistently (within each calendar year). Receipt of payments for compensation purposes, such as for consulting or travel, and higher dollar value of payments were also associated with increased prescribing.

1 June 2019 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
AMAaron P. Mitchell
Aaron P. Mitchell
JRJason S. Rotter
Jason S. Rotter
EPEsita Patel
Esita Patel
DRDaniel Richardson
Daniel Richardson
SWStephanie B. Wheeler
Stephanie B. Wheeler
DGDaniel A. Goldstein
Daniel A. Goldstein
Importance Significant controversy exists regarding whether physicians factor personal financial considerations into their clinical decision making. Within oncology, several reimbursement policies may incentivize physicians to increase health care use. Objective To evaluate whether the financial incentives presented by oncology reimbursement policies affect physician practice patterns. Evidence Review Studies evaluating an association between reimbursement incentives and changes in reimbursement policy on oncology care delivery were reviewed. Articles were identified systematically by searching PubMed/MEDLINE, Web of Science, Proquest Health Management, Econlit, and Business Source Premier. English-language articles focused on the US health care system that made empirical estimates of the association between a measurement of physician reimbursement/compensation and a measurement of delivery of cancer treatment services were included. The Risk of Bias in Non-Randomized Studies of Interventions tool was used to assess risk of bias. There were no date restrictions on the publications, and literature searches were finalized on February 14, 2018. Findings Eighteen studies were included. All were observational cohort studies, and most had a moderate risk of bias. Heterogeneity of reimbursement policies and outcomes precluded meta-analysis; therefore, a qualitative synthesis was performed. Most studies (15 of 18 [83%]) reported an association between reimbursement and care delivery consistent with physician responsiveness to financial incentives, although such an association was not identified in all studies. Findings consistently suggested that self-referral arrangements may increase use of radiotherapy and that profitability of systemic anticancer agents may affect physicians’ choice of drug. Findings were less conclusive as to whether profitability of systemic anticancer therapy affects the decision of whether to use any systemic therapy. Conclusions and Relevance To date, this study is the first systematic review of reimbursement policy and clinical care delivery in oncology. The findings suggest that some oncologists may, in certain circumstances, alter treatment recommendations based on personal revenue considerations. An implication of this finding is that value-based reimbursement policies may be a useful tool to better align physician incentives with patient need and increase the value of oncology care.

25 October 2023 in BMJ
Verified
Journal Article
Open access
PDF file
AMAaron P Mitchell
Aaron P Mitchell
SDStacie B Dusetzina
Stacie B Dusetzina
AMAkriti Mishra Meza
Akriti Mishra Meza
NTNiti U Trivedi
Niti U Trivedi
PBPeter B Bach
Peter B Bach
AWAaron N Winn
Aaron N Winn
Objective: To estimate the association between oncologists’ receipt of payments from the pharmaceutical industry and delivery of non-recommended or low value interventions among their patients. Design: Cohort study. Setting: Fee-for-service Medicare claims. Participants: Medicare beneficiaries with a diagnosis of incident cancer (new occurrence of a cancer diagnosis code in proximity to claims for cancer treatment, and no such diagnosis codes during a ≥1 year washout period) during 2014-19, who met additional requirements identifying them as at risk for one of four non-recommended or low value interventions: denosumab for castration sensitive prostate cancer, granulocyte colony stimulating factors (GCSF) for patients at low risk for neutropenic fever, nab-paclitaxel for cancers with no evidence of superiority over paclitaxel, and a branded drug in settings where a generic or biosimilar version was available. Main outcome measures: Receipt of the non-recommended or low value drug for which the patient was at risk. The primary association of interest was the assigned oncologist’s receipt of any general payments from the manufacturer of the corresponding non-recommended or low value drug (measured in Open Payments) within 365 days before the patient’s index cancer date. The two modeling approaches used were general linear model controlling for patients’ characteristics and calendar year, and general linear model with physician level indicator variables. Results: Oncologists were in receipt of industry payments for 2962 of 9799 patients (30.2%) at risk for non-recommended denosumab (median $63), 76 747 of 271 485 patients (28.3%) at risk for GCSF (median $60); 18 491 of 86 394 patients (21.4%) at risk for nab-paclitaxel (median $89), and 4170 of 13 386 patients (31.2%) at risk for branded drugs (median $156). The unadjusted proportion of patients who received non-recommended denosumab was 31.4% for those whose oncologist had not received payment and 49.5% for those whose oncologist had (prevalence difference 18.0%); the corresponding values for GCSF were 26.6% v 32.1% (5.5%), for nab-paclitaxel were 7.3% v 15.1% (7.8%), and for branded drugs were 88.3% v 83.5% (−4.8%). Controlling for patients’ characteristics and calendar year, payments from industry were associated with increased use of denosumab (17.5% (95% confidence interval 15.3% to 19.7%)), GCSF (5.8% (5.4% to 6.1%)), and nab-paclitaxel (7.6% (7.1% to 8.1%)), but lower use of branded drugs (−4.6% (−5.8% to −3.3%)). In physician level indicator models, payments from industry were associated with increased use of denosumab (7.4% (2.5% to 12.2%)) and nab-paclitaxel (1.7% (0.9% to 2.5%)), but not with GCSF (0.4% (−0.3% to 1.1%)) or branded drugs (1.2% (−6.0 to 8.5%)). Conclusions: Within some clinical scenarios, industry payments to physicians are associated with non-recommended and low value drugs. These findings raise quality of care concerns about the financial relationships between physicians and industry.

10 January 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AMAaron P. Mitchell
Aaron P. Mitchell
DGDaniel A. Goldstein
Daniel A. Goldstein